Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.
The new rating shows the stock is outpacing 98% of all stocks when it comes to the most important stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
On Thursday, Amphastar Pharmaceuticals stock soared 15% on robust Q3 results. The biotech stock is not in a proper entry point so it's best to wait for a buying pattern to present itself. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Looking For Winning Stocks? This 3-Step Routine
The stock earns a 99 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 99% of all stocks.
Its Accumulation/Distribution Rating of C shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
AMPH Earnings
The biotech company reported a 203% rise in earnings for Q3. It has now posted accelerating EPS gains for two consecutive quarters. Sales growth increased 50%, up from 18% in the prior report. That marks four quarters of increasing revenue gains.
Amphastar Pharmaceuticals stock earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
